291 related articles for article (PubMed ID: 15284298)
1. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
Lassila M; Seah KK; Allen TJ; Thallas V; Thomas MC; Candido R; Burns WC; Forbes JM; Calkin AC; Cooper ME; Jandeleit-Dahm KA
J Am Soc Nephrol; 2004 Aug; 15(8):2125-38. PubMed ID: 15284298
[TBL] [Abstract][Full Text] [Related]
2. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
Lassila M; Jandeleit-Dahm K; Seah KK; Smith CM; Calkin AC; Allen TJ; Cooper ME
J Am Soc Nephrol; 2005 Feb; 16(2):363-73. PubMed ID: 15625075
[TBL] [Abstract][Full Text] [Related]
3. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
[TBL] [Abstract][Full Text] [Related]
4. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation.
Usui HK; Shikata K; Sasaki M; Okada S; Matsuda M; Shikata Y; Ogawa D; Kido Y; Nagase R; Yozai K; Ohga S; Tone A; Wada J; Takeya M; Horiuchi S; Kodama T; Makino H
Diabetes; 2007 Feb; 56(2):363-72. PubMed ID: 17259380
[TBL] [Abstract][Full Text] [Related]
5. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
Mizuno S; Nakamura T
Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
[TBL] [Abstract][Full Text] [Related]
6. The protective effect of Salvia miltiorrhiza in an animal model of early experimentally induced diabetic nephropathy.
Lee SH; Kim YS; Lee SJ; Lee BC
J Ethnopharmacol; 2011 Oct; 137(3):1409-14. PubMed ID: 21856399
[TBL] [Abstract][Full Text] [Related]
7. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
Meier M; Park JK; Overheu D; Kirsch T; Lindschau C; Gueler F; Leitges M; Menne J; Haller H
Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378
[TBL] [Abstract][Full Text] [Related]
8. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.
Forbes JM; Thallas V; Thomas MC; Founds HW; Burns WC; Jerums G; Cooper ME
FASEB J; 2003 Sep; 17(12):1762-4. PubMed ID: 12958202
[TBL] [Abstract][Full Text] [Related]
9. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.
Candido R; Forbes JM; Thomas MC; Thallas V; Dean RG; Burns WC; Tikellis C; Ritchie RH; Twigg SM; Cooper ME; Burrell LM
Circ Res; 2003 Apr; 92(7):785-92. PubMed ID: 12623881
[TBL] [Abstract][Full Text] [Related]
10. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes.
Seo JY; Park J; Yu MR; Kim YS; Ha H; Lee HB
Am J Nephrol; 2009; 30(6):481-90. PubMed ID: 19786738
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).
Oldfield MD; Bach LA; Forbes JM; Nikolic-Paterson D; McRobert A; Thallas V; Atkins RC; Osicka T; Jerums G; Cooper ME
J Clin Invest; 2001 Dec; 108(12):1853-63. PubMed ID: 11748269
[TBL] [Abstract][Full Text] [Related]
12. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
[TBL] [Abstract][Full Text] [Related]
13. Extracellular matrix is modulated in advanced glycation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-β1 RAGE.
Serban AI; Stanca L; Geicu OI; Munteanu MC; Costache M; Dinischiotu A
J Diabetes; 2015 Jan; 7(1):114-24. PubMed ID: 24666836
[TBL] [Abstract][Full Text] [Related]
14. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
15. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.
Shiota A; Yamamoto K; Ohishi M; Tatara Y; Ohnishi M; Maekawa Y; Iwamoto Y; Takeda M; Rakugi H
Hypertens Res; 2010 Apr; 33(4):298-307. PubMed ID: 20186149
[TBL] [Abstract][Full Text] [Related]
16. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy.
Brizzi MF; Dentelli P; Rosso A; Calvi C; Gambino R; Cassader M; Salvidio G; Deferrari G; Camussi G; Pegoraro L; Pagano G; Cavallo-Perin P
FASEB J; 2004 Aug; 18(11):1249-51. PubMed ID: 15180953
[TBL] [Abstract][Full Text] [Related]
17. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
Wang A; Ziyadeh FN; Lee EY; Pyagay PE; Sung SH; Sheardown SA; Laping NJ; Chen S
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1657-65. PubMed ID: 17804483
[TBL] [Abstract][Full Text] [Related]
18. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.
Tan AL; Sourris KC; Harcourt BE; Thallas-Bonke V; Penfold S; Andrikopoulos S; Thomas MC; O'Brien RC; Bierhaus A; Cooper ME; Forbes JM; Coughlan MT
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F763-70. PubMed ID: 20015941
[TBL] [Abstract][Full Text] [Related]
19. Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content.
Thallas-Bonke V; Coughlan MT; Tan AL; Harcourt BE; Morgan PE; Davies MJ; Bach LA; Cooper ME; Forbes JM
Nephrology (Carlton); 2013 Jan; 18(1):47-56. PubMed ID: 23046363
[TBL] [Abstract][Full Text] [Related]
20. Hepato-/reno-protective activity of Chinese prescription Kangen-karyu through inhibition of AGE formation and fibrosis-related protein expression in type 2 diabetes.
Okamoto T; Park CH; Noh JS; Toriizuka K; Sei Y; Park JC; Yokozawa T
J Pharm Pharmacol; 2011 Jul; 63(7):952-9. PubMed ID: 21635261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
